Company: RPTX
Filing Date: 2025-11-17
Form Type: DEFA14A
Source: 0001193125-25-284040
Chunk: 164

Company: Repare Therapeutics Inc.
Filing Date: 2025-11-17
Form: DEFA14A
Chunk 164
---
 10.1 FORM OF D&O VOTING AND SUPPORT AGREEMENT November 14, 2025 XENO ACQUISITION CORP. 2200 Powell Street, Suite 310 Emeryville, California 94608 Dear Sirs/Madams:

| Re: | Voting and Support Agreement |

The undersigned understands that Xeno Acquisition Corp. (the “ Purchaser”), XenoTherapeutics, Inc., Repare Therapeutics Inc. (the “ Company”) and, solely for purposes of Section 9.15 thereof, XOMA Royalty Corporation wish to enter into an arrangement agreement dated as of the date hereof (the “ Agreement”) contemplating an arrangement (the “ Arrangement”) of the Company under Chapter XVI, Division II of the Business Corporations Act(Québec), the result of which shall be the acquisition by the Purchaser of all the issued and outstanding common shares of the Company (the “ Shares”). All capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to them in the Agreement.

| 1. | The undersigned hereby agrees, solely in his or her capacity as a securityholder of the Company and not in his                                                                                     
 or her capacity as an officer or director of the Company, from the date hereof until the earlier of (i) the Effective Time and (ii) the termination of the Agreement in accordance with its terms: |

| (a) | to vote or to cause to be voted all of the Subject Securities (as defined below) entitled to vote, including                                                                                                                                         
 any other such securities of the Company directly or indirectly acquired by or issued to the undersigned after the date hereof, (i) in favour of the approval of the Arrangement Resolution, the Alternate Resolution and any proposal to adjourn or 
 postpone the Meeting if such adjournment or postponement is proposed pursuant to and in compliance with the provisions of the Agreement; and (ii) against any Acquisition Proposal and any other matter which could reasonably be expected to        
 frustrate, breach, interfere with, prevent or delay the completion of transactions contemplated in the Agreement, including, but not limited to material transactions such as (A) any removal, replacement or increase in the board of directors of  
 the Company; (B) any recapitalization, arrangement, amalgamation or similar transaction of or involving the Company or any of its Subsidiaries; or (C) any change in the authorized or issued capital of the Company or any amendment of the         
 Company